Skip to main content

XXII

Stock

XXII

Stock
Consumer Staples
Tobacco

Performance overview

XXII Price
Price Chart

Forward-looking statistics

Beta
1.50
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

Company info

SectorConsumer Staples
IndustryTobacco
Employees61
Market cap$6.3M

Fundamentals

Enterprise value$6.5M
Revenue$23.9M
Revenue per employee
Profit margin-57.62%
Debt to equity153.49

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$1,212.10
Dividend per share
Revenue per share$958.44
Avg trading volume (30 day)$180K
Avg trading volume (10 day)$408K
Put-call ratio

Macro factor sensitivity

Growth+2.7
Credit+1.9
Liquidity+8.2
Inflation-5.9
Commodities-12.8
Interest Rates-6.4

Valuation

Dividend yield0.00%
PEG Ratio-0.43
Price to sales0.09
P/E Ratio-0.43
Enterprise Value to Revenue0.27
Price to book0.21

Upcoming events

Next earnings dayMay 13, 2025
Next dividend day
Ex. dividend day

News

Top 3 Risk Off Stocks That Could Blast Off This Month

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.

Benzinga (June 23, 2025)
3 Tobacco Stocks Grabbing Attention on Solid Industry Trends

The Zacks Tobacco industry companies have been benefiting from their pricing power and strength in smoke-free products amid an inflationary landscape. These upsides keep Philip Morris (PM), Altria Group (MO) and 22nd Century Group (XXII) well-placed.

Zacks Investment Research (February 23, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free